GSK plc has scored a notch on the respiratory syncytial virus (RSV) vaccine development leaderboard, beating rival Pfizer Inc. to a younger adult population. The US Food and Drug Administration on 7 June approved GSK’s RSV vaccine Arexvy in adults aged 50-59 who have medical conditions that put them at increased risk of severe RSV.
Key Takeaways
- GSK beat Pfizer to a new younger patient population for its RSV vaccine Arexvy with US FDA approval in adults aged 50-59.
- There are more than 13 million US adults aged 50-59 who have a medical condition that could increase their risk of severe RSV, according to GSK
The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) is expected to discuss vaccination recommendations in younger adults later in June, as well as broader recommendations on use of the vaccines relying on shared decision making with clinicians
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
